Federation Des Caisses Desjardins Du Quebec Dia Medica Therapeutics Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $17.5 Billion
- Q2 2024
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 230 shares of DMAC stock, worth $1,012. This represents 0.0% of its overall portfolio holdings.
Number of Shares
230
Previous 230
-0.0%
Holding current value
$1,012
Previous $637,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DMAC
# of Institutions
36Shares Held
3.87MCall Options Held
1.3KPut Options Held
1K-
Vanguard Group Inc Valley Forge, PA1.02MShares$4.48 Million0.0% of portfolio
-
First Manhattan CO New York, NY839KShares$3.69 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX483KShares$2.12 Million3.48% of portfolio
-
Bleichroeder LP New York, NY382KShares$1.68 Million0.41% of portfolio
-
Geode Capital Management, LLC Boston, MA237KShares$1.04 Million0.0% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $116M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...